| AEPCX | AFCMX | AEPCX / AFCMX | |
| Total Expense Ratio | 1.57 | 0.74 | 212% |
| Annual Report Gross Expense Ratio | 1.57 | 0.74 | 212% |
| Fund Existence | 25 years | 10 years | - |
| Gain YTD | 23.863 | 16.968 | 141% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 138B | 158M | 87,342% |
| Annual Yield % from dividends | 0.15 | 0.08 | 195% |
| Returns for 1 year | 16.12 | 13.85 | 116% |
| Returns for 3 years | 34.33 | 31.32 | 110% |
| Returns for 5 years | 6.62 | 8.79 | 75% |
| Returns for 10 years | 42.78 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SHSAX | 66.77 | 0.64 | +0.97% |
| BlackRock Health Sciences Opps Inv A | |||
| POLEX | 10.15 | 0.01 | +0.10% |
| Polar Capital Emerging Market Strs Instl | |||
| FBTTX | 33.48 | N/A | N/A |
| Fidelity Advisor Biotechnology M | |||
| ALABX | 13.55 | N/A | N/A |
| ALPS/Smith Balanced Opportunity A | |||
| GLVIX | 96.86 | -0.12 | -0.12% |
| Invesco Global Focus R6 | |||